HCG 5000 IU

DRAGON PHARMA HCG 5000 IU

Dragon Pharma HCG 5000 IU represents the gold standard in testicular recovery and fertility maintenance for athletes, bodybuilders, and men concerned about reproductive health in the United States. Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone structurally and functionally similar to luteinizing hormone (LH), making it an essential tool for preventing testicular atrophy during anabolic steroid cycles and facilitating recovery during post-cycle therapy (PCT). Each 2 mL vial contains 5000 International Units (IU) of highly purified HCG derived from recombinant DNA technology, manufactured under strict pharmaceutical standards to ensure maximum purity, biological activity, and reliability. Third-party laboratory testing confirms potency at 4768 IU per vial, demonstrating Dragon Pharma's commitment to quality control and accurate labeling. As one of the most widely used and trusted compounds in performance enhancement circles, HCG serves as both a preventive measure during cycles and a restorative agent during recovery periods.

DRUG COMPOSITION

Each vial contains 5000 International Units (IU) of Human Chorionic Gonadotropin as a lyophilized white powder. HCG is a glycoprotein hormone composed of 244 amino acids with a molecular weight of approximately 36.7 kDa, consisting of an alpha subunit (92 amino acids) identical to LH, FSH, and TSH, and a unique beta subunit (145 amino acids) that confers biological specificity. Dragon Pharma utilizes recombinant DNA technology for HCG production, ensuring superior purity and consistency compared to urinary-derived preparations. The product may contain small amounts of human albumin or other stabilizers to maintain structural integrity during lyophilization but contains no additional excipients or preservatives that could interfere with biological activity. The lyophilization process ensures extended shelf life while maintaining the delicate tertiary structure essential for receptor binding and signal transduction.

PHARMACEUTICAL FORM

Sterile lyophilized powder for injection in a 2 mL glass vial sealed with a rubber stopper and aluminum cap. The lyophilized form offers superior stability compared to pre-mixed liquid preparations, with extended shelf life and reduced risk of microbial contamination or hormone degradation. The powder reconstitutes quickly with bacteriostatic water or sterile saline, forming a clear solution suitable for subcutaneous or intramuscular injection. Each vial is individually packaged with tamper-evident seals and includes batch-specific quality control documentation verifying biological activity. The 2 mL volume allows for flexible reconstitution and accurate dosing—typically reconstituted with 1-5 mL of diluent to achieve concentrations suitable for precise administration. Special handling instructions emphasize gentle swirling rather than shaking to maintain glycoprotein integrity during reconstitution.

PHARMACEUTICAL GROUP AND ATC CODE

HCG belongs to the therapeutic category of gonadotropins (ATC code: G03GA). According to the WHO Anatomical Therapeutic Chemical Classification System, it falls under gonadotropins and other ovulation stimulants. In reproductive medicine, it's classified as a luteinizing hormone (LH) analog due to structural and functional similarities. For male applications, it's categorized as a Leydig cell stimulant that promotes testosterone production and spermatogenesis support. Unlike true LH which has a half-life of approximately 20-30 minutes, HCG's longer half-life (24-36 hours) makes it more practical for therapeutic use. This extended activity allows for less frequent dosing while maintaining consistent testicular stimulation, making it particularly valuable for managing steroid-induced hypogonadism and fertility preservation.

PHARMACOLOGICAL PROPERTIES

HCG exerts its primary effects through binding to the luteinizing hormone/choriogonadotropin receptor (LHCGR) on Leydig cells in the testes, stimulating testosterone production and supporting spermatogenesis. According to research published in the Journal of Clinical Endocrinology & Metabolism, HCG maintains testicular steroidogenesis and partially preserves spermatogenesis during exogenous testosterone administration by providing LH-like activity that bypasses hypothalamic-pituitary suppression. The hormone also exhibits weak thyroid-stimulating activity due to structural similarities with TSH. HCG's long half-life (24-36 hours compared to 20-30 minutes for endogenous LH) results from sialic acid residues that reduce hepatic clearance. This extended activity allows sustained testicular stimulation with less frequent dosing. Unlike direct testosterone administration which suppresses endogenous production, HCG stimulates natural testicular function while providing therapeutic androgen support.

THERAPEUTICAL INDICATIONS

Dragon Pharma HCG 5000 IU is indicated for: prevention of testicular atrophy during anabolic steroid cycles, stimulation of testosterone production in hypogonadal men, support of spermatogenesis and fertility preservation, facilitation of post-cycle therapy (PCT) and hypothalamic-pituitary-testicular axis (HPTA) recovery, treatment of cryptorchidism (undescended testes) in prepubertal boys (under medical supervision), management of male hypogonadotropic hypogonadism, enhancement of testicular volume and function, and as part of fertility treatment protocols. It's particularly valuable for bodybuilders and athletes using suppressive compounds, men seeking to maintain fertility while using performance enhancers, individuals undergoing PCT after anabolic cycles, and those with secondary hypogonadism seeking to stimulate endogenous testosterone production.

DOSES AND METHOD OF ADMINISTRATION

Reconstitute the 5000 IU vial with 1-5 mL of bacteriostatic water, gently swirling to dissolve. Standard dosing protocols: For testicular maintenance during cycles: 250-500 IU administered subcutaneously or intramuscularly every 3.5 days (twice weekly). For PCT and recovery: 500-1500 IU every other day for 2-3 weeks, then tapered. For fertility stimulation: 1500-5000 IU every other day (under medical supervision). For hypogonadism: 500-2000 IU 2-3 times weekly. Administration can be subcutaneous (abdominal, thigh) or intramuscular (gluteal, deltoid), with subcutaneous generally preferred for ease and comfort. Treatment duration varies: During cycles: continue throughout; For PCT: 2-4 weeks; For fertility: 8-24 weeks. Always begin with lower doses to assess individual response and estrogen conversion tendency. Higher doses may require division into multiple injections per week to minimize side effects.

CYCLE/STACKING

HCG integrates seamlessly with various compounds to optimize hormonal health and recovery. Combine with Aromasin to manage estrogen conversion from increased testosterone production. Stack with Nolvadex during PCT for comprehensive HPTA recovery combining testicular stimulation (HCG) and pituitary modulation (SERM). For enhanced fertility protocols, add HMG 150 IU to provide both LH (HCG) and FSH activity for complete spermatogenesis support. During testosterone replacement therapy (TRT), include Proviron to enhance androgen effects while maintaining fertility with HCG. For comprehensive metabolic support alongside hormonal therapy, combine with NAD+ to support cellular energy production in reproductive tissues.

POST CYCLE THERAPY

HCG serves as a cornerstone of effective post-cycle therapy by directly stimulating testicular testosterone production while the hypothalamic-pituitary axis recovers from suppression. The "HCG blast" protocol involves administering 500-1500 IU every other day for 2-3 weeks at the beginning of PCT, followed by traditional SERMs (Clomid, Nolvadex) for an additional 3-4 weeks. This approach jumpstarts testicular function before the pituitary fully recovers its ability to secrete LH. HCG is particularly crucial after cycles containing compounds that cause significant testicular atrophy (Deca, Trenbolone, oral steroids). However, prolonged HCG use during PCT may delay pituitary recovery due to negative feedback, so timing and duration must be carefully managed. Many protocols use HCG only during the first 2-3 weeks of PCT, then transition to SERMs alone to allow complete HPTA restoration.

SIDE EFFECTS

Common side effects include gynecomastia (breast tissue enlargement) due to increased testosterone aromatization to estrogen, fluid retention, acne, increased oiliness of skin, mood changes, headache, fatigue, and injection site reactions. Less common but serious side effects include ovarian hyperstimulation syndrome (OHSS) symptoms even in men (abdominal pain, swelling, nausea), allergic reactions, and thrombotic events. With prolonged high-dose use, Leydig cell desensitization may occur, reducing responsiveness to both HCG and endogenous LH. Unlike exogenous testosterone, HCG doesn't cause erythrocytosis (elevated red blood cell count) or significantly affect lipid profiles. Most side effects are dose-dependent and manageable with dosage adjustments, concomitant aromatase inhibitor use, or proper timing of administration relative to PCT protocols.

CONTRAINDICATIONS

Contraindications include known hypersensitivity to HCG or any component of the formulation. Not recommended for individuals with hormone-sensitive cancers (prostate, breast, testicular) unless under oncological supervision. Those with untreated thyroid or adrenal dysfunction should have these conditions optimized first. Men with primary testicular failure (primary hypogonadism) will not respond to HCG stimulation. Not for use in women who are pregnant or could become pregnant due to potential teratogenic effects. Individuals with severe renal or hepatic impairment should consult a healthcare provider before use. Prepubertal boys should only use under specific medical indications (cryptorchidism) with careful supervision to prevent premature epiphyseal closure. Not recommended for individuals with history of thrombosis or thromboembolic disorders.

OVERDOSE

Acute overdose primarily manifests as exaggerated hormonal effects: severe gynecomastia, significant fluid retention, mood disturbances, headache, and in extreme cases, symptoms resembling ovarian hyperstimulation syndrome (OHSS) even in men (abdominal distension, pain, nausea). In cases of significant overdose, discontinue use and monitor for thromboembolic events in susceptible individuals. Supportive care includes managing fluid balance, providing symptomatic relief for gynecomastia (ice packs, NSAIDs), and considering aromatase inhibitors to reduce estrogen conversion. No specific antidotes exist, but symptoms typically resolve as the hormone clears from the system (approximately 3-5 days for acute effects, longer for gynecomastia). Leydig cell desensitization from chronic overdose may require several weeks to reverse. Always follow recommended dosing guidelines and monitor for early signs of excessive stimulation.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE

Use strict aseptic technique for reconstitution and injection to prevent infection. Rotate injection sites regularly to prevent tissue damage or lipohypertrophy. Monitor for signs of excessive estrogen conversion (gynecomastia, fluid retention, emotional lability) and consider concomitant aromatase inhibitor use if needed. Regular blood tests to monitor testosterone, estradiol, LH, and FSH are essential during treatment. Semen analysis may be indicated when used for fertility purposes. Discontinue use if severe allergic reaction occurs. Those with history of seizures should use with caution due to potential androgenic effects on seizure threshold. Store reconstituted solution refrigerated at 2-8°C and use within 30 days. Avoid concurrent use with other potent gonadotropin stimulants unless under medical supervision. Men over 40 should have regular PSA monitoring when using HCG.

INTERACTIONS WITH OTHER DRUGS

Potentiates effects of other gonadotropins and androgens. Aromatase inhibitors (Arimidex, Aromasin) may be needed to manage estrogen conversion. Dopamine agonists (Caber) may be required if prolactin elevation occurs (though HCG has minimal prolactin effect). Glucocorticoids may reduce HCG effectiveness. Concurrent use with exogenous testosterone may reduce HCG's testicular stimulation due to combined negative feedback. Herbal supplements with estrogenic activity (soy, red clover) may exacerbate estrogen-related side effects. Always disclose all medications and supplements to healthcare providers when using HCG. Those using anticoagulants require closer monitoring due to potential effects on coagulation parameters with hormonal fluctuations.

PRESENTATION, PACKAGING

Dragon Pharma HCG 5000 IU is presented in sterile 2 mL glass vials with gray rubber stoppers and blue aluminum seals. Each vial contains 5000 IU of lyophilized Human Chorionic Gonadotropin. Product is available in packs of 1, 3, or 5 vials, often with bacteriostatic water included for reconstitution. Each vial is individually labeled with product name, strength (5000 IU/vial), batch number, expiration date, and unique serial number for authenticity verification. Packaging includes tamper-evident features and discreet outer packaging for privacy. Instructions for proper reconstitution (gentle swirling, not shaking) and administration are included. The blue color coding distinguishes it from other Dragon Pharma hormone products for easy identification. Larger pack sizes often include additional sterile water vials and insulin syringes for convenient administration.

STORAGE

Store unopened vials at 2-8°C (36-46°F) in refrigerator. Do not freeze. Protect from light exposure. After reconstitution, store at 2-8°C (36-46°F) and use within 30 days when reconstituted with bacteriostatic water. Do not use if solution appears cloudy, discolored, or contains particulate matter. Avoid temperature fluctuations and repeated freezing/thawing cycles. For travel, use insulated containers with cold packs. Long-term storage (over 6 months) should maintain constant refrigeration. Shelf life of unopened vials is 24 months when stored properly. Keep out of reach of children and pets. Do not use beyond expiration date printed on vial.

DELIVERY TO THE USA

All orders to the United States are shipped discreetly with guaranteed temperature-controlled delivery. We utilize specialized cold-chain shipping with temperature monitoring devices to ensure hormone integrity during transit. Most orders arrive within 7-10 business days with tracking and temperature data provided. Packaging is plain, unmarked, and includes insulated containers with cold packs for optimal temperature maintenance. We offer reshipment guarantee for orders lost in transit or compromised by temperature excursions. Express shipping options (3-5 business days) with enhanced cold-chain protection available. All packages require signature confirmation. Domestic reshipping services available for added privacy protection.

LEGAL STATUS

In the United States, HCG is classified as a prescription drug under the Food, Drug, and Cosmetic Act and is Schedule III controlled substance when intended for weight loss purposes. It is illegal to purchase or possess without a valid prescription from a licensed healthcare provider. However, for research purposes by qualified institutions, it may be obtained through appropriate channels. This product is sold for laboratory research only. Not for human consumption, diagnosis, or treatment of any disease. Purchasers assume all responsibility for compliance with local, state, and federal laws. In sports competitions, most organizations permit therapeutic use with appropriate medical documentation. Always consult with appropriate legal counsel regarding the status in your jurisdiction.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Dragon Pharma, Europe

EXTERNAL LINKS

• National Institutes of Health - HCG in Male Hypogonadism Treatment

PROFILE

• Chemical name: Human Chorionic Gonadotropin
• Molecular weight: 36.7 kDa (approximately)
• Chemical structure: Glycoprotein hormone with alpha and beta subunits
• Percentage of anabolic activity: Indirect via testosterone stimulation
• Percentage of androgenic activity: 0% (not androgenic directly)
• Active half life: 24-36 hours (intramuscular/subcutaneous administration)
• Recommended dosage: 250-1500 IU 2-3 times weekly
• Acne: Possible (via increased testosterone)
• Bloating (water retention): Common due to estrogen conversion
• HBR (Hepatobiliary-related): No direct hepatotoxicity
• Hepatic toxicity: None reported
• Aromatization: Does not aromatize, but increases testosterone which may
• Detection time: 7-10 days
• Anabolic/Androgenic Ratio: N/A (not anabolic steroid)
• Receptor specificity: Luteinizing hormone/choriogonadotropin receptor (LHCGR)
• Amino acid composition: 244 amino acids (alpha: 92, beta: 145)
• Source: Recombinant DNA technology (superior to urinary-derived)

Third Party Lab Test

2023-09-26

View Result

4768 IU